Human stem cell derived cardiomyocytes (hESC-CM) provide a potential model for development of improved assays for preclinical predictive drug safety screening. We have used multielectrode array (MEA) analysis of hESC-CM to generate multiparameter data to profile drug impact on cardiomyocyte electrophysiology using a panel of 21 compounds active against key cardiac ion channels. Our study is the first to apply multi-parameter phenotypic profiling and clustering techniques commonly used for high-content imaging and microarray data to the analysis of electrophysiology data obtained by MEA analysis. Our data show good correlations with previous studies in stem cell derived cardiomyocytes and demonstrate improved specificity in compound risk assignment over convention single-parametric approaches. These analyses indicate great potential for multi-parameter MEA data acquired from hESC-CM to enable drug electrophysiological liabilities to be assessed in pre-clinical cardiotoxicity assays, facilitating informed decision making and liability management at the optimum point in drug development.
Recent advances in methods for large-scale production of cardiomyocytes (CM) from human embryonic stem cells (hESC) and induced pluripotent stem cells (hiPSC) have generated significant interest among both drug developers and regulators in the potential of this cell model to provide improved methods for evaluating drug safety (Chi, 2013; Scott et al., 2013; Seiler et al., 2011) . Stem cell derived CMs have potential advantages over traditional cell and ex vivo models for drug safety assessment. Full and efficient assessment of cardiac liabilities for new drug development is not restricted to electrophysiological analysis of drug effects on hERG and other ion channels, which are a key focus for regulatory pre-clinical liability assessments, but must take a holistic account of structural and functional aspects of CM cell biology in surveying a wide range of mechanisms whereby a new chemical entity may perturb cardiac function. When used in combination with appropriate analytical techniques stem cell derived CMs provide an integrated pre-clinical human model capable of surveying a wide range of cardiac liabilities and cardiotoxicity mechanisms. This is in marked contrast to the varied and significant limitations of the disparate model systems widely used today; ion channel cell lines that provide high detection sensitivity, but only at the overexpressed target; animal cells and ex vivo models that can yield species discordances leading to false positives/negatives. The large-scale availability of human stem cell derived CMs has enabled the development of integrated cross-platform approaches to drug safety assessment using more detailed and informative multi-parameter analysis of drug impact on CM biology (Doherty et al., 2013; Pointon et al., 2013; Rana et al., 2012) .
Non-cardiovascular drugs associated with drug-induced ventricular arrhythmia (Torsades de Pointes; TdP) alter or delay cardiac repolarization. This delay in cardiac repolarization can be observed as the prolongation of the period between the start of Q wave and the end of the T wave (QT interval) on the electrocardiogram (ECG). Almost all drugs that delay cardiac repolarization and cause TdP have been shown to block the repolarizing hERG K + current. Consequently, the assessment of drug impact on the hERG K + channel has been a key focus of pre-clinical cardiac safety pharmacology testing. However, it is widely recognised that extensive focus on hERG has resulted in an overly high attrition rate (false positives) in drug development and that drug pharmacology studies using multiple ion channel effects (MICE) models (Gintant, 2011; Gintant et al., 2006; Kramer et al., 2013) are likely to be more predictive of clinical drug response where compensatory drug actions on one or more other ion channels mitigate or abolish QT prolongation due to hERG blockage (Mirams et al., 2011) . Additionally, overly focusing on hERG as the principal suspect for QT prolongation and/or TdP runs the risk of false-negative assignments for drugs such as Alfuzosin that act at ion channels other than hERG (Lacerda et al., 2008) . Stem cell derived CMs therefore provide a means to advance the development of MICE assays 446 CLEMENTS AND THOMAS in an integrated human model using a variety of analytical platforms.
Several studies using hESC-and hiPSC-derived CMs for evaluation of drug liabilities against CM electrophysiology have been published using a variety of analytical platforms including measurement of action potential duration (APD) by manual patch clamping (Caspi et al., 2009; Peng et al., 2010) , impedance measurement of contraction (Abassi et al., 2012; Guo et al., 2011a Guo et al., , 2013 , and multi-electrode array (MEA) measurement of extracellular field potential (FP) (Asai et al., 2010; Braam et al., 2010; Caspi et al., 2009) . In a recent study by GlaxoSmithKline (Harris et al., 2013) , a hiPSC-CM MEA assay was reported to be more sensitive in detecting drug impact on repolarization than the rabbit wedge system for the majority of drugs tested and CM data showed good correlation with standard functional electrophysiology measurements for both hERG and Na + channel blockers.
MEA analysis provides a data rich high-throughput method for characterizing drug effects on CM function producing extracellular FP waveform data from cell monolayers or clusters which are analogous to clinical ECG recordings. Analysis of these traces provides data on field potential duration (FPD), an in vivo analogue of the QT interval, spike amplitude (SA), beat interval, beat rate, and other descriptors, which may be used individually or in combination to define a cellular phenotype resulting from drug treatment.
In this study, we have used multi-parameter data analysis techniques, including phenotypic profiling and hierarchical cluster analysis, commonly used to analyse rich data sets arising from high content cell imaging (Thomas, 2010) , to analyse MEA data and to characterize the effects of a range of drugs in hESC-derived cardiomyocytes (hESC-CM). The panel of 21 drugs (Table 1) included examples of hERG blockers (Astemizole, Terfenadine, and Terodiline), which were withdrawn from clinical use due to QT prolongation and/or proarrhythmia and others (e.g., Dofetilide, Moxifloxacin, and Sotalol) still in clinical use. We also used drugs known to prolong QT via ion channels other than hERG (Alfuzosin, BAY K8644, FPL64176), drugs active at multiple ion channels (Quinidine, Ranolazine, and Verapamil), and drugs specific for Na + (Lidocaine and Mexiletine) and Ca 2+ channels (Nifedipine). MEA data from hESC-CM showed good agreement with previously published studies in hiPSC-CM and phenotypic profiling and hierarchical clustering of multi-parameter data allowed separation of compounds by ion channel impact and had excellent agreement with previously reported torsadogenic propensity classifications (Redfern et al., 2003) .
MATERIALS AND METHODS
MEA assay. MEA 48 -well plates (Axion BioSystems) were prepared by pipetting 4 l droplets of fetal bovine serum (FBS) onto each electrode region and incubating for 1.5 h at room temperature. Following adsorption of FBS to the surface the droplet was replaced with 4 l fibronectin solution (12.5 g/ml, BD Biosciences) and plates incubated at 37
• C for 2 h. Cytiva Plus CMs (GE Healthcare) were seeded direct from thawed cryovials onto prepared MEA plates using 4 l of cell suspension at 1.5 x 10 7 viable cells/ml (60,000 cells per well) in RPMI 1640/B27 (Life Technologies) medium. Once cell attachment was complete (2-3 h) wells were carefully filled with RPMI 1640/B27 medium taking care not to disturb the plated cells. The plates were then incubated at 37
• C/5% CO 2 . On day 4 post-thaw half the seeding medium was replaced with fresh medium and cells were used for MEA recordings on day 5 post-thaw (Fig. 1A) . FP measurements were recorded from spontaneously beating hESC-CM monolayers using a Maestro MEA system (Axion BioSystems) at 37
• C. Data was sampled at 12.5 kHz and filtered with a Butterworth 1 Hz-2 kHz band-pass filter. Cells were sequentially exposed to increasing concentrations of test drugs using the following regime: 0-12 min, baseline equilibration, recording 100 s of extracellular FP data at the end of the period: 12-24 min, equilibration with lowest drug concentration with 100 s recording at the end of period. Drug treatment was repeated at 24-36, 36-48, 48-60 , and 60-72 min for each successive increase in drug concentration (Fig. 1B ). Data were collected from 4 to 6 wells of CMs for each test drug and normalized to data obtained from time-matched wells treated with DMSO to correct for any time and/or vehicle dependent effects. Raw FPD measurements were also corrected using Fredericia's rate correction algorithm, (FPDcF) where FPDcF = FPD/Beat Period 0.33 . Beat regularity, or coefficient of variance of the beat period, was calculated as the standard deviation of the beat period record in 100 s, divided by the mean of the beat period in that same period.
MEA data analysis.
No exclusion criteria were applied to the data collected in this study. All data collected were used to generate mean data. Statistical analysis was performed using Prism V4.03 (GraphPad) and hierarchical clustering of multiparameter MEA data was performed using Spotfire (TIBCO).
Impedance beating recordings. hESC-CMs were seeded direct from thawed cryovials onto fibronectin-coated 96-well impedance plates at 50,000 viable cells per well in RPMI 1640/B27 medium. Impedance recordings were performed at 50 h post-thaw. Impedance measurements were recorded from spontaneously beating hESC-CM monolayers using a CardioExcyte 96 system (Nanion Technologies) at 36
• C. Data was sampled at 10 kHz.
Ca
2+ imaging. Fluo-4 AM (50 g) was dissolved in 50 l 20% Pluronic F-127 DMSO solution (Invitrogen) and added to 2.5 ml RPMI/B27 medium at 37
• C. Fluo-4 AM solution (20M, 100 l) was added to hESC-CMs (day 5 post-thaw) seeded in 100 l RPMI/B27 medium and incubated for 30 min at 37
• C/5% CO 2 . The media was then removed and replaced Immunofluorescence. hESC-CMs were fixed in 4% paraformaldehyde for 30 min at room temperature and then permeabilized and blocked in a 1:10 mix of Perm wash buffer (PwB):PBS, 0.1 mg/ml human IgG, and 5% goat serum for 30 min. Cells were incubated with ␣-actinin (1:200, Sigma A7811) and/or Troponin I (1:400, Millipore MAB1691) primary antibodies in PwB, overnight. The primary antibody solution was aspirated and the cells were incubated in Alexa Fluor 488 GAM IgG1 (1:400, Invitrogen A21121) and Alexa Fluor 647 GAM IgGy2b (1:400, Invitrogen A21242) in PwB for 1 h. Cells were stained with 5M Hoechst 33342 (Sigma) prior to imaging on IN Cell Analyser 2200 and DeltaVision OMX Imaging System (GE Healthcare).
RESULTS

Characterization of the hESC-CM
hESC-CM stained for troponin I and ␣-actinin showed the expected distribution of these key contractile components (Figs. 2A and 2B), appearing as a pattern of alternating fibrous striations across the length of the cells, a hallmark of functional myocytes. When seeded on MEA plates the hESC-CM formed a uniform monolayer on top of the electrode array (Fig. 2C ) providing a spontaneously beating syncytium of cells (Fig. 2D ) that can be readily evaluated for drug effects on CM electrophysiology. Cells stained with 10M Fluo-4 AM showed intracellular Ca 2+ transients consistent with the spontaneous beating frequency of the hESC-CM monolayer (Fig. 2E) .
The spontaneous beating characteristics of the hESC-CM were evaluated on MEA plates at 37
• C. MEA plates contain electrodes embedded in the culture surface of each well to measure fluctuations in extracellular FP generated from spontaneously beating hESC-CM (Fig. 2C) . The resulting FP waveform is analogous to an in vivo ECG trace, which measures the change in voltage on the body surface generated by ionic currents that flow through the heart. The FP waveform (Fig. 3A) comprises a sharp transient spike associated with Na + influx and membrane depolarization, followed by a shallower ramp during Ca 2+ influx and ending with a repolarization wave that corresponds to K + efflux. FPD, measured from the initial Na + spike to the maxima of the K + repolarization wave, has been shown to correlate with APD measurements from in vitro patchclamp analysis both by data comparison (Halbach et al., 2003) and by direct measurement of APD and FPD in the same device (Fendyur and Spira, 2012) and also with QT measurements (Guo et al., 2011b; Harris et al., 2013) performed in vivo using ECG. Additional analysis of the extracellular voltage waveform yields further descriptive parameters including SA, beat period, and beat regularity.
To establish the baseline characteristics of spontaneously contracting hESC-CM 144 MEA wells were seeded with hESC-CM with 122 (85%) of the wells producing spontaneously beating monolayers for FP waveform analysis (Figs. 3B-E). The well-to-well variability of the hESC-CM generated FP waveform was as follows: FPD 422 ± 71 ms, SA 2.41 ± 0.78 mV, beat period 1.31 ± 0.17 s, and beat regularity 0.006 ± 0.016 (mean ± SD).
Ion Channels that Underlie Spontaneous FP Waveform of hESC-CM
A fundamental understanding of the pharmacological characteristics of hESC-CM is required before this model can be integrated into pre-clinical arrhythmic risk assessment assays. A recent paper has cautioned the adoption of these cells on the basis of manual patch-clamp experiments, which reported poor sensitivity to Na + and IKs (KvLQT1 + minK) channel blockade (Qu et al., 2013) . The summation of multiple ion channel currents underlies the cardiac action potential (some of which are illustrated in Fig. 4A ). To determine the usefulness of a hESC-CM model, the effect of a series of selective ion channel blockers on the spontaneous FPD was tested. Na + channel block by 3M Mexiletine reduced SA and induced a moderate increase in the FPD, but not when the FPD is corrected for a change in beat period; FPDcF ( 1B ) consistent with blockade of an excitatory current during the action potential upstroke and in agreement with previously reported studies in hiPSC-CM (Harris et al., 2013) . Nifedipine, an L-type Ca 2+ channel blocker, induced a concentration-dependent shortening of the FPD and a concordant decrease in beat period ( Fig. 4D and Supplementary  fig. 1C ). This decrease in beat period seen with Ca 2+ channel blockade is also consistent with previous findings (Guo et al., 2011a) and is hypothesized to be the result of differences in Ca 2+ handling between hESC/hiPSC-CM and adult CMs.
Conversely, the Ca 2+ channel activator, BAY K8644, induced a concentration-dependent prolongation of the FPD and a concordant increase in beat period (Fig. 4E and Supplementary fig. 1D ). E-4031, a specific hERG K + channel blocker, prolonged the FPD at 3nM and suppressed spontaneous activity at concentrations higher than 30nM ( Fig. 4F and Supplementary fig. 1E ). The selective IKs (KvLQT1 + minK) channel blocker, JNJ282, caused a small but significant FPD prolongation at 3nM, consistent with the smaller contribution of this ion channel to CM membrane repolarization ( Fig. 4G and Supplementary fig. 1F ). Finally, we tested for functional ␤-adrenergic receptor signalling using isoproterenol. Isoproterenol induced a concentration-dependent shortening of the FPD and a concordant decrease in beat period, which was reversed by the ␤-adrenergic receptor antagonist, Atenolol, to a value not significantly different to pre-drug control (p > 0.5; paired t-test; Fig 4H and Supplementary fig. 1F ). Data from vehicle (DMSO) control wells showed a low baseline drift, with FPD values increasing by 4.0 ± 1.6% over the 72 min drug treatment period ( Fig. 4B and Supplementary fig. 1A ). Despite some well-towell variability of the hESC-CM generated FP waveform ( Fig.  3 and Supplementary fig. 1 ), once normalized, the magnitude of compound-induced responses from a single well is representative of the other replicates (Supplementary fig. 2 ).
Drug-Induced Perturbation of FPD (Single Parameter
Analysis) The focus of previous hESC/hiPSC-CM MEA studies has been primarily on the analysis of dose-dependent drug effects on FPD (Asai et al., 2010; Harris et al., 2013; Meyer et al., 2004) . The 21 drugs evaluated in this study represent a diversity of drug classes with known activities against a variety of ion channels (Table 1) riety of changes correlating with known single or multiple ion channel activities (Fig. 5) . The Ca 2+ channel blockers Nifedipine and Verapamil decreased FPD, as did the ␤-adrenergic agonist Isoproterenol, whereas the Ca 2+ channel activators BAY K8644 and FPL64176 induced a large increase in FPD. The IKs channel blockers JNJ282 and JNJ283 increased FPD as did the Na + channel blockers Lidocaine and Mexiletine, though to a far lesser extent.
Drugs known to block the hERG K + channel all (with the exception of the dual hERG and Ca 2+ channel blocker Verapamil) induced FPD prolongation, with the majority of compounds including E-4031, Quinidine, Sotalol, and Moxifloxacin giving dose-dependent increases in FPD across the full range of concentrations tested. Other hERG blockers, e.g., Dofetilide, Terfenadine, and Terodiline, produced an increase in FPD at low drug concentrations followed by reduction in FPD to below control values at higher doses.
Terfenadine has been shown to exhibit hERG blocking properties at concentrations below 100nM and inhibits Na V 1.5 at higher concentrations (IC 50 6.9M) (Liu et al., 2012) . In this study, Terfenadine exhibited impacts on CMs consistent with concentration-dependent inhibition of hERG and Na + currents; 100nM Terfenadine increased FPD by 22.9 ± 5.6% whereas at 1000nM FPD was reduced by 14.3 ±5.3% with a decrease in SA of 56.2 ± 5.7%. These findings coincide with data from MEA analysis of Terfenadine treated hiPSC-CM (Harris et al., 2013) , which showed FPD prolongation at 100nM and reduction in SA and shortening of FPD at 1000nM.
For a pre-clinical arrhythmic risk assay to be enabling in drug discovery, a quantitative system for ranking new drug candi- dates by their predicted risk of causing cardiac arrhythmias has to be developed, refined, and validated. Two notable studies in the literature have made significant progress along this path. Redfern and colleagues (2003) devised a "safety margin" from hERG (I Kr ) block assays, whereby a 30-fold difference in a compound's hERG IC 50 value relative to its free plasma concentration during clinical use (ETPC unbound ) was generally predictive of cardiac safety. More recently, Guo and colleagues (2013) devised their own predicted pro-arrhythmic scoring system by correlating compound-induced irregular beating in a hiPSC-CMs impedance-based assay with the clinical efficacious concentration (C eff ).
To determine the relative value of a pre-clinical hESC-CM MEA assay for predicting risk of TdP in clinical use we first calculated the lowest concentration of each test compound that induces a 20% increase in FPD (IFPD 20 ; Fig. 5, dashed line) . The C eff for the respective test compound was then divided by the IFPD 20 to generate a predicted risk score (PRS; Table 2 ) and the 21 tested drugs were ranked in descending order of PRS. Antiarrhythmic drugs expected to delay cardiac repolarization and drugs withdrawn from the market due to TdP (compounds in Redfern categories 1 and 2, respectively) were ranked highest with PRS ≥1.6. Compounds that have been shown to prolong QT yet with little or no evidence of inducing arrhythmias were ranked intermediately, with 0.19 ≤ PRS ≤1.2. Drugs that do not induce QT prolongation were ranked lowest. Lidocaine, a Na + channel blocker, was a notable exception with a PRS of 3.6. Lidocaine does not clinically induce TdP and this assessment based on FPD alone would incorrectly assign a high-risk score. In the case of Lidocaine (10M), the increase in FPD over the 20% threshold was accompanied by a significant increase in beat period. Correction of the FPD to account for chronicity changes yielded an FPDcF value not significantly different to the matched DMSO control (compare Supplementary fig. 3 with fig. 5 ). When a revised PRS was generated for all 21 compounds using the lowest concentration of each test compound that induces a 20% increase in FPDcF (rather than the raw FPD measure), the relative assigned scores had excellent agreement with previously reported torsadogenic propensity classifications (Table 3) .
Multi-Parameter Signal Analysis of Drug-Induced Effects
Although analysis of FPD alone is informative and may identify drugs with potential to induce QT prolongation at therapeutic concentrations, a single parameter is not adequately descriptive of the often complex effects of drugs in modulating CM electrophysiology. When the data collected from the 21 compounds tested in this study was visualized on parallel coordinate plots clearly differing phenotypic profiles emerged correlating with expected ion channel blocking activity (Fig. 6) . Analysis of FPD in combination with beat period, SA, and FPDcF showed a variety of positively and negatively correlated dose-dependent drug effects on these four parameters.
The Na + blockers Mexelitine and Lidocaine caused a modest prolongation of FPD but had a large impact on SA; Mexiletine (3M) increased FPD by 6.8 ± 6.3% and decreased SA by 40.0 ± 11.6% and Lidocaine (10M) increased FPD by 21.5 ± 3.2% and decreased SA by 58.4 ± 10.7%. It has been reported previously that hESC-CMs show poor sensitivity to Na V 1.5 block (Qu et al., 2013) , with 3M Mexiletine yielding a 10% increase in depolarization duration (QRS complex duration in ECG) in isolated rabbit heart whereas 10.3M Mexiletine was required to achieve a 10% detection threshold for Vmax in patch clamping of hESC-CM subjected to current injection (which may in some circumstances reduce sensitivity of detection of Na + channel blockers). However, in our MEA study Mexiletine produced a >10% decrease in SA at 1M with 3M Mexiletine producing a 40% reduction in SA (Fig. 6 ). These data also emphasize the benefit of collecting multi-parameter data sets to detect drug impact where a single measurement (e.g., FPD) may yield a false negative or marginal result.
When multi-parameter MEA data is used to generate phenotypic profiles as shown in Figure 6 , Na + channel blockers (navy blue graphs) can be readily distinguished from hERG K + channel blockers (pink graphs). Astemizole and other hERG blockers typically showed significant prolongation of FPD and FPDcF with lesser effects on SA and minimal impact on beat period. This approach to data analysis enables false assignments made on the basis of a drug effect on a single parameter, such as the Lidocaine false positive discussed above, to be identified.
The other phenotypic multi-parameter profiles observed were as follows. Ca 2+ channel block, by Nifedipine or Verapamil, produced a dose -dependent increase in beat rate with an accompanying reduction in beat period, FPD, and FPDcF (pale blue graphs; Fig. 6 ). The inverse profile was observed for Ca 2+ channel activators, BAY K8644 and FPL64176 (red graphs). Blockade of IKs channel, by JNJ282 or JNJ303, had minimal effect on beat rate or beat interval, but increased SA, FPD, and FPDcF (green graphs). Na + channel activation by Alfuzosin produced a dose-dependent increase in FPD, FPDcF, and beat period with an accompanying reduction in SA (orange graph). This method of analysis of multi-parameter MEA data provides good characterization of drug induced impact on CM electrophysiology, is diagnostic of single or multiple ion channel inhibition and/or activation, and is an efficient method of screening candidate drugs for cardiac liability.
Clinical QT prolongation and TdP risk may not relate simply to drug impact on a single type of ion channel and additive or counteracting current inhibition or activation may contribute to dose-dependent variation in drug liability. Consequently, monitoring the effects of drugs in an integrated human ion channel milieu, as found in hESC-CM, is now generally acknowledged to be an improved pre-clinical tool for predicting cardiac safety liabilities (Guo et al., 2013) over the analysis of individual ion channels in over-expressing cell lines.
Verapamil, used clinically for treatment of hypertension and angina, is a commonly used example of a drug with dual ion channel activity. Verapamil blocks hERG current with an IC 50 of 143nM (Zhang et al., 1999) but any potential effect on QT prolongation is negated by inhibition of L-type Ca 2+ channels at similar concentrations. Treatment of hESC-CM with Verapamil produced a dose-dependent decrease in FPD (Fig. 6 ) with an 81.4 ± 7.9% reduction in FPD at 100nM. At this concentration Verapamil increased the spontaneous CM beat rate by 81.1 ± 16.8%, a similar increase to that reported for hiPSC-CM (Harris et al., 2013) .
Although much of the focus of pre-clinical safety studies is on hERG, some compounds produce significant QT prolongation through action at other ion channels. Alfuzosin, an ␣1-adrenergic antagonist used to treat benign prostatic hyperplasia, delays cardiac repolarization not by blocking hERG potassium current, but by increasing Na + current, a drug liability that was not detected by hERG IC 50 and porcine Purkinje fiber safety studies prior to NDA submission. Later evaluation (Lacerda et al., 2008) demonstrated that 1M Alfuzosin increased APD in a rabbit Purkinje fiber assay by 11.5 ± 3.2% and prolonged the QT interval in a Langendorff rabbit heart model by 10-12%. In the present study, Alfuzosin produced an increase of 31.9 ± 4.7% in FPD at 1M with minimal (3.6 ± 2.1%) reduction in SA. FPD prolongation (20.4 ± 4.9%) was also observed at 300nM and higher concentrations produced significant reduction in SA (Fig. 6 ).
Because drugs with common known mechanisms of action showed similar phenotypic profiles (Fig. 6) , we next tested whether hierarchical clustering based on Euclidian distance could be employed as an unbiased method of predicting the identity of ion channel(s) perturbed on drug exposure. Clustering (Fig. 7) was carried out using data from the lowest drug concentration causing a ≥20% increase in FPD (≥20% decrease in FPD for Verapamil, Isoproterenol, and Nifedipine), or in the absence of a measured change in FPD of ≥20%, the highest tested drug concentration. The compounds were then ranked by the channel activators. Ranking of compounds by multi-parameter clustering demonstrates the potential for this multi-parameter approach to characterize new drug candidates and enables false assignments made on the basis of a drug effect on a single parameter, such as the Lidocaine false positive discussed above, to be mitigated. Drug ranking by hierarchical clustering showed good agreement with Redfern et al. (2003) classifications with a few key exceptions, notably Tolterodine and Terodiline which have been previously reported to require inclusion of clinical exposure data to resolve their relative risks ). The PRS approach described above using FPD or FPDcF at drug doses reflecting clinical use effectively resolved this anomaly.
To compare rankings obtained by unsupervised hierarchical clustering ( Fig. 7) with previously published cardiac risk assessments, we compared the rankings of the six drugs in this study that overlap with the drugs analysed by Redfern et al. (2003) and Mirams et al. (2011) . Data for hERG IC 50 , calcium IC 50 , and C max from the Mirams MICE study were used to analyse the correlation between hERG IC 50 /C max , an indicator of the likelihood of drug impact on hERG occurring at therapeutic plasma levels, and calcium IC 50 /hERG IC 50 , an indicator of the potential for Ca 2+ current inhibition offsetting APD or QT prolongation due to hERG block (Fig. 8) . Superimposition of Redfern TdP classifications showed good correlation with hERG IC 50 /C max and calcium IC 50 /hERG IC 50 confirming the utility of MICE analysis. Examination of compound rankings obtained by hierarchical clustering of multi-parameter MEA data from our study (Fig. 7) showed good correlation with MICE and TdP drug classifications. Compounds with low cluster rankings, Verapamil (1), Nifedipine (3), and Mexiletine (5) fell in the upper left quadrant of the MICE/TdP correlation plot, whereas drugs with high cluster rankings, Terfenadine (12), Quinidine (17), and Dofetilide (21) were all placed in the lower right quadrant (Fig. 8) . This analysis and comparison of the data from the present study with previously published and widely recognised approaches to cardiac drug liability assessment confirms that multiple ion channel assessment, as provided by MEA analysis, provides additional predictivity over single channel hERG assays and that multi-parameter analysis and hierarchical clustering, as described in the current study, provides compound rankings that correlate well with previously reported TdP risk. We believe that the data presented from this study indicates very significant potential for two complementary analytical approaches that are suitable for assessing drug cardiac liabilities and torsadogenic risk at different stages in drug development. The multi-parameter profiling and clustering strategy allows mechanistic identification and provides a means to rank compounds for risk potency in the absence of clinical exposure data. Where clinical data is available, calculation of risk based on one or more parameter thresholds at clinically relevant drug concentrations provides further confirmation and resolution of risk rankings.
The analyses reported here indicate that compound profiling based on multi-parameter MEA data acquired from hESC-CM holds significant promise for enabling more predictive drug risk assignment. Furthermore, combination of these MEA profiles with profiles descriptive of functional and structural toxicity obtained by high-throughput imaging could provide an even greater insight into the wide range of potential drug impacts on cardiac physiology.
DISCUSSION
There is growing recognition among drug developers and regulators that existing approaches to prediction of TdP have limited utility and predictivity (Johannesen et al., 2013) , have not evolved to take account of recent developments in stem cell models and analytical techniques, and that there may be opportunities to exploit such advances to develop an improved and comprehensive in vitro proarrhythmia assay (FDA/CSRC/HESI, 2013). It has been acknowledged for some time that using hERG assays in predictive isolation only partially addresses the possible drug impacts on ion channel currents that may modify the CM action potential and that hESC-CMs provide an integrated system (Asai et al., 2010; Braam et al., 2010) , in which new drugs may be tested with no a-priori assumptions of individual ion channel contributions as are required for engineered cell and in silico models.
Although debate continues over the maturation state of stem cell derived CMs and how well they reflect the physiology of mature CMs in vivo, considerable amounts of characterisation data have been generated by a range of groups indicating that these cells express the major ion channels of interest to drug developers, safety pharmacologists and regulators and respond appropriately to pharmacological challenges (Honda et al., 2011; Ma et al., 2011; Peng et al., 2010) . Further research will no doubt shed more light on phenotypic similarities and differences as well as decreasing the gap between the two. Recent com-
FIG. 7.
Hierarchical clustering of MEA data. Multi-parameter data from compounds at the lowest drug concentration giving a change in FPD of ≥20% over DMSO or the highest tested drug concentration were used to rank and cluster compounds with similar effects on CM electrophysiology. In other words, the drugs were ranked according to the magnitude of perturbation in FPDcF, SA, beat period, and beat rate that accompanied the change in FPD. Cluster analysis showed good grouping of compounds with respect to known ion channel impact. Redfern TdP classifications (2003) are indicated to the right of the heatmap; Redfern categories for clinical drugs in this study not listed in Redfern et al. (2003) were assigned as (X) based on the rules therein.
parison of drug responses of stem cell derived CMs with historical pre-clinical data (Harris et al., 2013) showed excellent correlations with published data from standard cardiac electrophysiological methods. Current experience and data supports a view that stem cell derived CMs have potential to be a "fit-forpurpose" pre-clinical model with a number of key advantages over existing systems;
CLEMENTS AND THOMAS
FIG. 8.
Correlation of hierarchical clustering ranking with MICE and TdP risk. The six drugs ( ) in this study overlapping with the compounds analysed by Redfern et al. (2003) and Mirams et al. (2011) (•) are arrayed by hERG IC 50 /Cmax (the therapeutic index for the drug with respect to hERG) and calcium IC 50 /hERG IC 50 (reflecting the likelihood that Ca 2+ channels will be affected in concert with hERG). Hierarchical cluster rank values from this study (Fig. 7) are shown within the square symbols. Redfern TdP classifications are indicated by symbol colours. Combination of the Mirams data with Redfern classifications confirms the utility of multiple ion channel assessment with compounds with low Redfern scores in the upper left and high scores in the lower right. Overlay of the drug rankings from our present study (indicated by the numbered symbols in Fig. 8 ) confirms that the hierarchical clustering approach used provides an excellent match with previously reported findings. Overall therefore Figure 8 conveys two messages; firstly that multiple ion channel assessment, as provided by MEA analysis, provides additional predictivity over single channel hERG assays and secondly that multi-parameter analysis and hierarchical clustering, as described in the current study, provides compound rankings that correlate well with previously reported TdP risk.
(1) human model avoiding known historical false-negative issues in animal ex-vivo systems (e.g., Terfenadine and Cisapride in Purkinje fibers) (2) integrated ion channel environment suitable for MICE drug assessment (3) robust and reproducible large-scale supply of material, in contrast to limitations and variations inherent in the preparation of primary tissue models (4) compatible with a wide range of analytical platforms enabling data integration for comprehensive surveillance of drug cardiac electrophysiological, functional, and structural liabilities.
MEA provides a rapid and efficient approach to analysis of CM electrophysiology providing higher throughput and reduced operator skill requirements compared with traditional patchclamp methods. MEA also enables experimental protocols including long-term chronic drug exposure, use of mixed cell populations in 2D and 3D cultures, and analysis of drug impact on cell-to-cell transmission of electrical signalling that are precluded by standard patch-clamp methodology. The combination of MEA and stem cell derived CMs therefore provides an attractive approach to screening candidate drugs for cardiac liability. In this study, we have use high-throughput MEA data recording coupled with multi-parameter analysis methods to profile the impact of a panel of 21 drugs active against a range of ionic cur-rents in hESC-CM. Although a study of only 21 drugs is of comparatively small scale and more work with a larger diverse compound set will be required for a full analysis of clinical predictivity, the approach presented here using multi-parametric analysis techniques in an integrated ion-channel model has clear potential to improve predictivity over single parameter measurements in disparate isolated assay systems.
The drugs used in this study include a number of clinical and experimental hERG blockers including examples (Astemizole and Terodiline) that have been withdrawn from clinical use and drugs that remain in therapeutic use but which cause clinical QT prolongation to a greater or lesser extend (Moxifloxacin, Dofetilide, Ranolazine, Sotalol, Quinidine, and Tolterodine). All hERG blockers increased FPD to a varying degree in hESC-CM, with some compounds (E-4013, Moxifloxacin, Tolterodine, and Quinidine) showing increasing FPD with dose whereas others (Dofetilide, Terfenadine, and Terodiline) showed bidirectional modulation of FPD (Fig. 5) . In some cases (e.g., E-4031 and Tolterodine) treatment of cells with higher doses of hERG blockers abolished spontaneous beating precluding further measurements, whereas with other compounds producing greater changes in FPD or SA (e.g., Astemizole and Dofetilide) CM beating was retained. These findings emphasize the need to test a range of drug concentrations in order to avoid the assignment of a false negative on the basis of a single concentration test.
The MEA data from this study using hESC-CM shows good agreement for drug responses with that previously obtained from MEA analysis of hiPSC-CM (Harris et al., 2013) , although there are key differences in terms of data stability and sensitivity that may reflect differences in cell type and/or MEA instrumentation and methodology used. Data from hESC-CMs in our study showed a lower baseline drift from DMSO controls and higher drug responses than previously reported for hiPSC-CM (Harris et al., 2013) . DMSO control FPD values increased by 4.0 ± 1.6% over the 72 min drug treatment protocol (Fig. 4B , left panel) compared with a 10-12% increase in FPD over 75 min reported with hiPSC-CM. For equivalent drug concentrations and exposure times FPD prolongation with Terfenadine (100nM) in this study was 22.9 ± 5.6% compared with 10% for hiPSC-CM, 10nM E-4031 caused a 38.1 ± 8.7% increase in FPD compared with 11% in hiPSC-derived cells and Quinidine (1M) increased FPD by 69.6 ± 22% compared with 20% (Harris et al., 2013) . The lower baseline drift and increased responses observed in this study may reflect improved stability of hESC-CM in a 48-well MEA system with data from replicates acquired in parallel, compared with hiPSC-derived cells analysed in a single well MEA system with sequential data collection.
Not all compounds that delay cardiac repolarization and increase FPD are torsadogenic. However, combination of FPD data with drug clinical exposure levels to generate predictive risk scores (PRS) generated compound rankings ( Table 2) that showed good agreement with clinical experience and correctly ranked compounds (e.g., Terodiline and Tolterodine) where in vitro data in isolation is not discriminatory. PRS ranking using FPDcF (Table 3) further refined drug rankings by removing potential false positives arising from chronicity changes (Lidocaine). A ≥1.2-fold margin between a drug's efficacious concentration and the concentration sufficient to induce a 20% increase in FPD (IFPD 20 ) was predictive of high torsadogenic risk (e.g., Dofetilide and Terfenadine). Compounds that have been shown to prolong QT yet with little or no evidence of inducing arrhythmias were ranked intermediately, with 0.14 ≤ PRS ≤1.1 (e.g., Moxifloxacin and Alfuzosin). Drugs that do not clinically induce TdP were ranked lowest (e.g., Verapamil and Mexiletine).
To integrate and analyse multi-parameter data from a range of drug concentrations in an automated strategy suitable for use in a screening environment, we used using multi-parameter analysis methods commonly used for microarray and high-content imaging to profile CM drug impacts to enable detailed characterisation of drug impact on CM electrophysiology, including complex perturbations arising from the changing balance of drug inhibition or activation at different ion channels across a range of drug doses.
Parallel coordinate plots (Wegman, 1990 ) allowed complex drug dose effects on hESC-CM electrophysiological phenotypes to be visualized and classified by drug effects on key cardiac ion channels (Fig. 6) . Hierarchical clustering using the same multi-parameter data can be performed using a chosen threshold on one or more parameters to group and rank compounds relative to defined criteria. To rank compounds by potential liability for TdP we applied a threshold of ≥20% increase in FPD to select drug concentrations for clustering of associated data (Fig. 7) . Hierarchical clustering allows synergistic or opposing drug impacts reflecting multiple ion channel activities to contribute to drug risk classification, which may be refractory to analysis using single parameter analysis. Inclusion of both FPD and FPDcF, together with SA, beat rate, and beat period generated phenotypic signatures that increase the predictivity of MEA analysis and avoid possible errors in risk assignment arising from artefactual drug impacts on a single parameter. In this study hERG blockers consistently increased FPD with minimal effects on beat period (Fig. 7) and consequently produced closely matched FPD and FPDcF values. On clustering these compounds were clearly separated from compounds, e.g., Lidocaine, which produced increased FPD due to changes in beat period and beat rate and resulting differential FPD and FPDcF values.
Clustering of multi-parameter data effectively grouped drugs by ion channel impact and ranked compounds in accordance with Redfern TdP classifications (Fig. 7) . To further compare cluster rankings with previously published data, we examined the correlation between the cluster ranking scores for six compounds in this study, which were used in both the Redfern et al. TdP risk (2003) and the Mirams et al. MICE (2011) studies (Fig.  8) . Drug rankings from hierarchical clustering showed good agreement with published MICE and TdP data and classifications confirming the utility of multi-parametric MEA analysis for drug impact and liability analysis. We believe that this form of analysis will prove useful in identifying drug cardiac liabilities in a screening environment allowing new candidate drugs to be classified and ranked with respect to cardiac liability in the absence of clinical drug exposure data. At later stages in drug development when therapeutically effective drug plasma concentrations have been established re-examination of MEA data and the use of clinical exposure data to generate PRS rankings as described here may be used to refine risk predictions.
Our study demonstrates the utility of MEA analysis of hESC-CM, coupled with multi-parametric data analysis, to provide rapid high-throughput profiling of drug impact on cardiac electrophysiology, matching the needs of the pharmaceutical industry to assess drug liability early in the drug discovery process. Comprehensive surveillance of cardiac drug liabilities requires the use of a range of assays and instruments to detect drug impact on one or more electrophysiological, structural, or functional elements of CM biology. hESC-CMs provide a single integrating cell model compatible with a wide range of analytical platforms to achieve comprehensive analysis of drug liability. Using hESC-CM allows electrophysiological liabilities to be assessed in MEA screening assays in parallel with complementary phenotypic imaging screens for functional and structural cardiotoxicity to enable informed decision making and liability management at the optimum point in drug development.
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